ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial

ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial

Background: FLOT and CROSS are effective neoadjuvant regimens for esophageal cancer patients. Chemotherapy (FLOT) is aimed to have merely a systemic effect whereas neoadjuvant chemoradiotherapy (CROSS) achieves good locoregional response with clinically complete response (cCR) rates up to 33% [1]. T...

Full description

Bibliographic Details
Main Authors: Charlène J. van der Zijden, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Joost J.M.E. Nuyttens, J. Jan B. van Lanschot, Bas P.L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Contemporary Clinical Trials Communications
Subjects:
Esophageal cancer
Esophagogastric junction
Adenocarcinoma
Oligometastatic disease
Chemotherapy
Chemoradiotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865422000515

Internet

http://www.sciencedirect.com/science/article/pii/S2451865422000515

Similar Items